However, both of the HER2+ breast cancer cell lines with mutant p53 (BT474 and MDA-MB453) were insensitive to the inhibition of WIP1 (Fig. 5b, c), although they also have 17q23 amplicon. This evidence concerns the gene ERBB2 and breast carcinoma.